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ABSTRACT
We describe a physical mRNA mapping strategy
employing fluorescent self-quenching reporter
molecules (SQRMs) that facilitates the identification
of mRNA sequence accessible for hybridization with
antisense nucleic acids in vitro and in vivo, real time.
SQRMs are 20–30 base oligodeoxynucleotides with
5–6bpcomplementaryendstowhicha50 fluorophore
and 30 quenching group are attached. Alone, the
SQRM complementary ends form a stem that holds
the fluorophore and quencher in contact. When the
SQRM forms base pairs with its target, the structure
separates the fluorophore from the quencher. This
event can be reported by fluorescence emission
when the fluorophore is excited. The stem–loop of
the SQRM suggests that SQRM be made to target
natural stem–loop structures formed during mRNA
synthesis.Thegeneralutilityofthismethodisdemon-
stratedbySQRMidentificationoftargetablesequence
within c-myb and bcl-6 mRNA. Corresponding anti-
sense oligonucleotides reduce these gene products
in cells.
INTRODUCTION
A major obstacle to employing antisense oligonucleotides for
post-transcriptional gene silencing in mammalian cells is the
apparent randomness with which they silence target mRNA
expression. In addition to concerns related to intracellular
delivery of nucleic acid molecules, oligonucleotide stability
and hybridization kinetics, we have hypothesized that an
extremely important element of this problem is our inability
to reliably identify hybridization accessible nucleotides within
the targeted mRNA. This failure arises as a result of mRNA
secondary and tertiary structure which cannot be predicted
in vivo, and is complicated by RNA-associated proteins.
Molecular beacons, containing a loop sequence ﬂanked by
complementary stems,were designed byTyagiandKramer(1)
to identify target sequences with high speciﬁcity, while exhib-
iting a low background signal. We have reported that base
pair sequence-speciﬁc ﬂuorescent probes (designed after
‘molecular beacons’), we have called self-quenching reporter
molecules (SQRMs) (Figure 1), can hybridize with an mRNA
target in a living cell and reveal gene expression ‘real time’
(2). This has been conﬁrmed by others (3). A logical extension
would be to employ the intracellular signal as a means of
locating single-stranded, hybridization accessible regions in
any mRNA molecule in real time. Complementary nucleic
acids directed to sites by this method should then reliably
silence the expression of the encoding gene by a variety of
mechanisms (4).
A number of strategies have been developed to identify
physically accessible regions within a given mRNA molecule.
These include the use of random oligonucleotide libraries to
probe for accessible sites, identiﬁed by subsequent RNase H
cleavage fragments of the predicted size, mRNA hybridization
to oligonucleotide arrays and algorithm-generated RNA struc-
ture models based on free energy predictions (4). The general
utility of each of these approaches remains unclear, and none
can be followed in real time, or in living cells.
Here, we report the successful use of SQRMs to identify
hybridization accessible sites with the mRNA structure of
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doi:10.1093/nar/gni024three different targets: transcription factors c-myb (5,6) and
bcl-6 (7,8) and tyrosine receptor kinase c-kit (9). All three
targets were chosen because of their potential therapeutic util-
ity in treating different forms of human carcinoma (10–13).
Multiple SQRMs were developed for each of these targets and
a small percentage of these SQRMs were found to have an
adequate signal-to-noise ratio to indicate hybridization with
mRNA (>5:1). When introduced into living cells, antisense
oligodeoxyribonucleotide (ODN) molecules directed to these
sites allowed a decrease in mRNA and protein expression,
as judged by real-time PCR and western blots.
MATERIALS AND METHODS
ODN and SQRM synthesis
ODNs were synthesized in the University of Pennsylvania
Cancer Center Nucleic Acid Facility on an Expedite
TM
8909 Nucleic Acid Synthesis System (Applied Biosystems)
using standard phosphoramidite chemistry [bcl-6 antisense
ODNs (AS ODNs) obtained from Integrated DNA
Technologies]. The SQRM complements to the AccessSearch
outputted RNA sequences are synthesized with 30-C7-4-(40-
dimethylaminophenylazo)benzoicacid(DABCYL)Controlled
Pore Glass (Glen Research) used as support and a ﬂuorescein
phosphoramidite (Cruachem) for 50 end modiﬁcation (Table
1). All ODNs and SQRMs were HPLC-puriﬁed. SQRMs were
numbered according to the following convention: the SQRM’s
number designator corresponds to the 50 base of mRNA to
which the 30 base of the SQRM complements, the adenine of
the initiation codon is base (+1), and the base 50 of the initi-
ation A is designated ( 1), no zero base. The full descriptor is
characterized by the number of the ﬁrst 50 RNA base involved
in a duplex with the probe, an arrow to indicate the direction of
hybridization of the probe to the mRNA and a second number
that corresponds to the 30-most base involved in the helix.
In vitro SQRM hybridization
The genes were cloned into pcDNA3 plasmids (Invitrogen;
bcl-6 clone was a kind gift from R. Dalla-Favera,
Figure 1. SQRMdesignandreaction.(a) Concept:toexploitthetraditionalstem–loopstructureoftheSQRMs,acomputeralgorithm(‘AccessSearch’) searchesan
entire sequence of mRNA for complementary sequences of a desired length (stems) that are separated by a proscribed distance (loop). (b) Chemistry: the
complementary sequences are synthesized as SQRM possessing 50-fluorescein and 30 DABCYL groups. In the absence of target, quenching of fluorescence
occurs. Once hybridization of the loop sequence to a complementary target takes place, the moieties are separated and fluorescence can be detected.
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plasmids using the T7 RNA Polymerase RiboMax
TM Kit (Pro-
mega). SQRMs (100 nM) were incubated for 30 min at 37 C
with (1 mM) in vitro transcribed RNA, (10 mM) ODN (positive
control) or (1 mM) scrambled ODN (negative control) target in
SQRM buffer (100 mM Tris–HCl, pH 7.5, 2 mM MgCl2).
Total RNA was isolated from Louckes cells (bcl-6 expressing
human Burkitt lymphoma cell line kindly provided by Jill
Lacy, Yale University) and K562 cells (non-expressing)
with QIAgen RNeasy Kit (Qiagen). Fluorescence emission
was monitored using a Packard FluoroCount Microplate
Fluorometer (Packard Instrument Company).
In vitro assays
Separate plasmids containing coding sequence for c-myb
and luciferase are mixed in a 5:1 molar ratio and added to
the TnT1 rabbit reticulocyte lysate coupled transcription/
translation system (Promega) with Redivue L-[
35S]methionine
(Amersham) and 1 U of RNase H (USB). Control ODN
(50-TGTCTGGTTGCAAAGCCTGGCATAAAGACA-30)and
AS ODN 321 350 were added toseparate mixtures at38- and
63-foldmolarexcess.Followingincubationat30 Cfor90min,
aliquots were resolved on 10% SDS–PAGE and scanned on a
Storm PhorsphorImager (Molecular Dynamics). In vitro tran-
scribed bcl-6 mRNA (1 mM) was preincubated with (1 mM)
SQRM 1190 1222 or two control sequences in SQRM buffer
at 37 C for 10 min. RNase H buffer and enzyme were added,
incubated at 37 C for 10 min, and the reaction was stopped by
adding Proteinase K and run on a 1% agarose gel.
Western blotting
Adherent hamster ﬁbroblast Tk
 ts13 cells (American Type
Culture Collection) engineered to express human c-myb from
anexogenousvectorweregrowninDMEMsupplementedwith
10% heat-inactivated fetal calf serum, 1% L-Glutamine, 0.5%
Penicillin/Streptomycin and Geneticin (G418; 1250 mg/ml)
(Invitrogen). Cells were treated with AS ODN/Lipofectin1
(Invitrogen) complex for 5 h, washed twice with cold PBS
and incubated overnight at 37 C. Cells were incubated at
4 C for 30 min in lysis buffer (50 mM Tris–HCl, pH 7.6,
150 mM NaCl and 1% Triton X-100) containing a protease
inhibitor cocktail tablet (Roche Diagnostics). Each sample
contained 50 mg total protein and was resolved by 7.5%
SDS–PAGE. Transfer to a polyvinyl diﬂuoride membrane
(Bio-Rad) was performed in glycine transfer buffer (192 mM
glycine, 25 mM Tris, pH 8.8) for 1 h at 100 V and western blot
was carried out with ECL Plus
TM Western Blotting Detection
Reagents Kit (Amersham). Antibodies used: 1:1000 dilution
anti-c-Myb mAb (Upstate Biotechnology), peroxide-labeled
anti-mouse antibody (1:3000 dilution; Upstate Biotechnology)
Table 1. Sequences of SQRMs identified using the AccessSearch program
Sequence
c-myb-targeted SQRMs
SQRM 321 350 50-F-ACAGACCAACGTTTCGGACCGTATTTCTGT-D-30
SQRM 772 799 50 F-CATGTTCCATACCCTGTAGCGTTACATG-D-30
SQRM 1179 1207 50 F-AGAAACACTCCAATTTATAGATTCTTTCT-D-30
SQRM 1454 1481 50 F-AGATGCTACCTCAGACACCCTCTCATCT-D-30
SQRM 1649 1676 50-F-GTCTGAATACCCAACTGTTCACGCAGAC-D-30
SQRM 1898 1915 50 F-TCTCAGCCCGGACGCTGGTCATGTGAGA-D-30
SQRM 1965 1992 50-F-GTTGAGGAATGATATATCCCAAGTCAAC-D-30
SQRM 1982 2011 50-F-CATTCATGAAAAGTTTCATGTTGAGGAATG-D-30
bcl-6-targeted SQRMs
SQRM 518 548 50-F-CTGGGGGCAAAGGCTCTGCTCTCACACCCAG-D-30
SQRM 831 864 50-F-GGCTGAGGGGGCAGCAGGTTTGAGGCCCTCAGCC-D-30
SQRM 832 863 50-F-GCTGAGGGGGCAGCAGGTTTGAGGCCCTCAGC-D-30
SQRM 834 861 50-F-TGAGGGGGCAGCAGGTTTGAGGCCCTCA-D-30
SQRM 1039 1073 50-F-GCCTGGAGGATGCAGGCATTCTTACTGCTGCAGGC-D-30
SQRM 1190 1222 50-F-AGGCTCGTGGGGAAAGGCGGCCCAGCTCAGCCT-D-30
SQRM 1367 1392 50-F-GCTCTCGCTGCTGCTGCGGGGAGAGC-D-30
SQRM 1816 1841 50-F-ACCTGTACAAATCTGGCTCCGCAGGT-D-30
SQRM 1821 1853 50-F-CGGAGGTGGGCCACCTGTACAAATCTGGCTCCG-D-30
SQRM 2121 2141 50-F-AAGCATCAACACTCCATGCTT-D-30
c-kit-targeted SQRMs
SQRM 39 64 50-F-TCTGGACGCGAAGCAGTAGGAGCAGA-D-30
SQRM 137 163 50-F-TAATCTCGTCGCCCACGCGGACTATTA-D-30
SQRM 287 304 50-F-CGTGTTTGTTGGTGCACG-D-30
SQRM 351 381 50-F-TTTCCCATACAAGGAGCGGTCAACAAGGAAA-D-30
SQRM 580 607 50-F-TCAGGATGAATTTTTCCGACAGCACTGA-D-30
SQRM 663 683 50-F-TCTTCCCCTTCCCTAAGAAGA-D-30
SQRM 807 837 50-F-TGAACTGATAGTCAACGTTGCCTGACGTTCA-D-30
SQRM 924 946 50-F-AGATATTAATGAATCCTTTATCT-D-30
SQRM 962 994 50-F-CTACATTTTCTCCATCGTTTACAAATACTGTAG-D-30
SQRM 1093 1116 50-F-TCTGATATTACTTTCATTCTCAGA-D-30
Stems are bold; F, fluorescein; and D, DABCYL.
The full descriptor of SQRM is characterized by the number of the 50 base of mRNA to which the 30 base of the SQRM complements RNA, an arrow indicating the
directionofhybridizationoftheprobe,andasecondnumberthatcorrespondstothe30-mostbaseinvolvedintheduplex[adenineofRNAinitiationcodonisbase(+1),
and the base 50 of the initiation A is designated ( 1), no zero base].
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Products).
Microinjection
Tk
 ts13 cells were plated in 35 · 10 mm round dishes at
30–40% density 1 day before injection. Individual cells
were viewed under an Olympus AX70 inverted microscope
(Olympus America). Cytoplasmic SQRM injections (2 mM)
wereperformedwithaMicromanipulator5171andFemtoJet1
Microinjector (EppendorfAG). Injection volume was regu-
lated by injection pressure (260 hPa), injection time (0.3 s)
and compensation pressure (86 hPa). Images were captured
with a CoolSnap digital camera (Roper Scientiﬁc). IPLab
Imaging software package (Scanalytics) was used for imaging
and quantitation of the ﬂuorescence intensity.
RESULTS
SQRM design considerations
Thestructuralfeaturesofthe SQRM suggest arational strategy
for locating target sequences. An algorithm that scans the
cDNA sequence for complementary sequences of length (X),
andseparatedbyinterveningsequenceformingaloopoflength
(Y), was developed (Figure 1). Targeting SQRM to such loca-
tions provided two theoretical advantages. First, natural com-
plements might be good targets of intra-molecular duplex
formation within mRNA creating a loop available for hybrid-
ization. Second, if the SQRMs were fully complementary
to the mRNA target, the possibility of the ﬂuorophore and
quencher contacting each other as a result of dangling from
the non-hybridized DNA arms would be minimized. We had
noted that some SQRMs failed to generate their maximal
predicted ﬂuorescence (deﬁned as the ﬂuorescence emitted
by a fully DNase-digested SQRM), even when incubated
with up to a 5-fold excess of target (data not shown). One
explanation is that if the 50 and 30 ends of the SQRM are not
complementary to the mRNA target, the two stem fragments
(5 unpaired bases) and linkers (with 10 or more single bonds)
provide enough length and ﬂexibility to allow the ﬂuorophore
and quencher to contact each other while the loop portion is
hybridized to the target. This was conﬁrmed by building a
molecular model using Insight II1 (Biosym Technologies,
San Diego, CA) (data not shown). This model suggests that
the SQRM must be fully complementary to the mRNA target.
In vitro screening for hybridization accessible regions
To evaluate the utility of the SQRM design program, we tested
itsabilitytoidentifyaccessible sequence inthemRNAofthree
therapeuticallyrelevantgenes:c-myb,bcl-6andc-kit. Thepro-
gram was initially instructed to ﬁnd complementary sequences
4–5 bases in length, separated by 18–20 nt in accord with ori-
ginal recommendations for designing molecular beacons (1).
Later searches were broadened to ﬁnd SQRMs with longer
‘stems’andshorter‘loop’regions.Between8and10sequences
were identiﬁed for targeting within each mRNA (Table 1).
To carry out the in vitro screening assay, SQRMs were
added to (1 mM) in vitro transcribed mRNA. Each SQRM
assay included complementary and scrambled DNA target
controls. A 10 mM concentration of complementary oligonuc-
leotide, a positive control, was used to ensure that the SQRM
would achieve a high signal-to-noise ratio. The scrambled
ODN was incubated with SQRMs at a 1 mM concentration,
since this negative control was compared directly to the
SQRM results with in vitro transcribed RNA. ‘Scrambled’
ODNs were designed by replacing each base with its comple-
mentary base in the same 50 to 30 direction. The ﬂuorescence
was monitored in a plate reader equilibrated to 37 C. Signal-
to-noise ratios for all reactions can be found in Table 2.
Eight SQRM sequences were identiﬁed for testing with the
full-length [1923 nt plus  100 bases of the 30-untranslated
region (30-UTR)] in vitro transcribed c-myb mRNA (Figure 2).
SQRM 321 350 exhibited a signal-to-noise ratio of >5:1
(12.0 – 3.8:1). The other c-myb SQRM failed to hybridize
with their target sequence as revealed by their baseline, or
lower, ﬂuorescence. SQRMs 1965 1992 and 1982 2011
were directed to the 30-UTR region of the c-myb sequence
and showed a low signal-to-noise ratio (1.3 – 0.6:1 and
1.2 – 0.3:1, respectively). Whether targeting to the 30-UTR
would be unfavorable in general was not established.
Ten SQRMs each were synthesized to map the full-length,
2.4 kb, bcl-6 mRNA and a fragment of the human c-kit mRNA
( 21 to 1228 of the 2931 nt coding sequence). In the case of
bcl-6, only SQRM 1190 1222 showed a favorable signal-
to-noise ratio (14.5 – 1.5:1; Figure 2). The c-kit mapping
SQRMs had arms of either 4 or 5 bases and intervening
sequences ranging from 10 to 23 nt. Three of the ten SQRMs
gave sufﬁcient signal to indicate that they had hybridized
with the mRNA. These were c-kit SQRMs 663 683,
807 837 and 962 994 (Figure 2). The ‘loop’ lengths of
these molecules were 11, 21 and 13 nt, respectively, suggest-
ing that this parameter at least was quite permissive with
respect to mapping utility.
Evaluation of predicted sequence accessibility:
in vitro assays
To evaluate the utility of SQRM mapping for the identiﬁcation
of hybridization accessible sequence, ODNs complementary
to sequence identiﬁed as being available for hybridization
were synthesized and targeted to c-myb and bcl-6 mRNAs.
We ﬁrst evaluated the ability of a speciﬁcally targeted ODN to
direct RNase H-mediated cleavage of the mRNA to which it
had been directed in a rabbit reticulocyte lysate transcription/
translation system. This system was employed to better model
the effect that cellular proteins might have on ODN hybrid-
ization. In the ﬁrst series of experiments, we examined the
ability of an AS ODN corresponding to c-myb SQRM
321 350 to direct RNA cleavage in comparison with a
scrambled sequence not homologous to the c-myb or luciferase
genes. Separate plasmids expressing full-length c-myb cDNA
and luciferase mRNA (positive control) were mixed in a 5:1
molar ratio. This mixture was then added to the reticulocyte
lysate along with AS ODN 321 350, or a scrambled ODN,
at 38- and 63-fold molar excess to the predicted amount
of protein the system would produce (14). Equal amounts
of post-translation product from each reaction mixture were
analyzed by electrophoresis in a single polyacrylamide gel.
A PhosphorImage of this gel indicated that AS ODN
321 350, in the presence of RNase H, completely abolished
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63-fold molar excess, the highest ODN concentration
employed, luciferase protein was reduced  5-fold in the
reaction mixture containing AS ODN 321 350, but this is
in comparison with an  14-fold reduction in c-Myb protein.
At the highest scrambled ODN concentration (63-fold), some
non-speciﬁc decrease of the c-Myb and luciferase proteins was
also noted (2.5- and 1.5-fold reductions, respectively).
The efﬁcacy of targeting the bcl-6 transcript was evaluated
in vitro using two different assays. We ﬁrst evaluated the
ability of a SQRM to direct simple RNase H-mediated cleav-
age of an mRNA. In this experiment, in vitro transcribed
mRNA was incubated with SQRM 1190 1222, or with
two sense SQRM corresponding to non-opening locations,
831–864 and 1367–1392 (Figure 4a). As expected, bcl-6
SQRM 1190 1222 directed cleavage of the 2.4 kb bcl-6
transcript, yielding two fragments of the expected sizes,  1.1
and  1.3 kb, in an agarose gel. Speciﬁcity of cutting was
demonstrated by the fact that neither of the control sequences
had any effect on the mRNA.
Figure 2. mRNAfluorescence assay.(a) EightSQRMswereidentifiedto targetthefull-length,1923nt humanc-mybRNA;twoweretargetedto the 100basesof
the 30-UTR region and overlap each other by a few bases. One of these SQRMs, 321 350, possesses a signal-to-noise ratio of >5:1, indicating that it opens when
presented with a full-length RNA target. (b) Six SQRMs were hybridized with in vitro transcribed human bcl-6 targeted mRNA (2.4 kb). Of these SQRMs,
1190 1222 was shown to open, exhibiting a signal-to-noise ratio of  15:1. (c) Ten SQRMs were identified for a 1249 base fragment of the  2900 nt sequence of
humanc-kitmRNA.WhenhybridizedwithinvitrotranscribedRNA,three(SQRMs663 683,807 837and962 994)haveasignal-to-noisethatis>5:1.Allc-kit
experiments were performed in triplicate; correction for background was not made.
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RNA derived from Louckes Burkitt’s Lymphoma cells, which
express the bcl-6 gene, and K562 BCR/ABL-1 (+) myeloid
leukemia cells, which do not. Fluorescence was monitored
using a plate reader (Figure 4b). An ODN completely com-
plementary to the SQRM served as the arbitrary 100% ﬂuor-
escence control. As expected, SQRM ﬂuorescence increased
in the Louckes cell RNA when compared with that observed in
the K562 RNA. Speciﬁcity was further demonstrated by the
observation that ﬂuorescence was proportional to the amount
of RNA in which the SQRM was incubated. The signal-
to-noise ratio for SQRM 1190 1222 when incubated in
40mg of Louckes RNA was 2-fold higher than when incubated
in 20 mg of RNA.
Evaluation of predicted sequence accessibility:
in vivo assays
The results of the in vitro assays were encouraging, but it was
required to demonstrate that they would accurately predict a
targeted AS ODN ability to diminish mRNA expression in
living cells. This was carried out in TK
 ts13 cells engineered
to express c-myb, and the bcl-6 expressing Louckes cells.
Ac - myb targeted AS ODN corresponding to opening
SQRM 321 (complementary to nucleotides 326–345) and
an AS ODN corresponding to non-opening SQRM 970 (com-
plementary to nucleotides 983–1000) were transfected into
the TK
 ts13 cells. Levels of protein expression were
monitored by western blot and quantitated (Figure 5). Treat-
ment with AS ODN 326 345 caused a decrease in the protein
expression in direct proportion to the amount of the AS ODN
added to the cultures. Concentrations of 0.3 mM were capable
of reducing protein expression  70% compared with the level
of untreated cells. In contrast, AS ODN 983 1000 did not
bring about more than a 20% inhibition of the c-Myb protein.
The results are in complete accord with the results obtained
from the in vitro mapping assays.
Bcl-6 targeted AS ODNs protected by phosphorothioate
linkages between the ﬁve outermost bases were nucleoporated
into the Louckes cells. Delivery efﬁciency was assessed using
ﬂuorescein-labeled ODNs and was judged to be  95%, with
preservation of cell viability at  90% (data not shown). Con-
trol cells were subjected to the nucleofection procedure but in
the absence of ODN. Quantitative real-time PCR was used to
measure any resulting changes in mRNA expression; reaction
was performed in triplicate each time for bcl-6 and 18S rRNA.
When treated with the AS ODN 1190 1222 (corresponding
to an opening SQRM), the cellular bcl-6 mRNA exhibited a
7-fold decrease in expression (data not shown). These results
were conﬁrmed by western blot analysis. The Bcl-6 protein
expression was decreased by 80% compared with control
cell values following treatment with AS ODN 1190 1222
(data not shown). There were no signiﬁcant differences in
the bcl-6 mRNA expression levels in the control populations.
The scrambled control ODN, and AS ODN 1816 1841,
corresponding to a non-opening SQRM, also decreased bcl-6
Figure 3. In vitro transcription and translation assay. Incubation of rabbit
reticulocyte lysate with a c-myb AS ODN that corresponds to SQRM
321 350 decreases in vitro production of protein. Lanes 4 and 5 have been
normalized to the luciferase (Luc) control band to show that there is no
detectable presenceof c-Myb protein.In the absenceofexogenousDNA,there
are no radiolabeled proteins at the molecular weights expected for c-Myb and
luciferase.
Table 2. SQRM signal-to-noise ratios
Signal-to-noise ratios RNA ODN SCR
c-myb-targeted SQRMs
SQRM 321 350 (n = 20) 12.0 – 3.8 32.9 – 9.8 1.4 – 0.4
SQRM 772 799 1.3 – 0.4 34.8 – 10.6 1.1 – 0.3
SQRM 1179 1207 1.3 – 1.2 3.1 – 1.4 1.2 – 0.4
SQRM 1454 1481 0.9 – 0.4 4.5 – 1.4 1.3 – 0.4
SQRM 1649 1676 0.8 – 0.2 7.8 – 1.2 0.9 – 0.2
SQRM 1898 1915 0.9 – 0.2 16.2 – 1.9 0.9 – 0.2
SQRM 1965 1992 (n = 3) 1.3 – 0.6 12.4 – 5.4 0.9 – 0.5
SQRM 1982 2011 (n = 3) 1.2 – 0.4 10.4 – 2.3 5.1 – 6.8
bcl-6-targeted SQRMs
SQRM 518 548 2.3 – 0.8 70.6 – 16.0 2.0 – 0.6
SQRM 831 864 1.8 – 0.2 33.0 – 4.2 1.3 – 0.2
SQRM 832 863 1.1 – 0.1 57.6 – 6.6 1.6 – 0.2
SQRM 834 861 4.4 – 2.4 150.6 – 61.2 1.9 – 0.8
SQRM 1039 1073 2.2 – 0.5 39.2 – 8.6 2.7 – 0.6
SQRM 1190 1222 14.5 – 1.6 57.6 – 5.6 2.2 – 0.4
SQRM 1367 1392 1.1 – 0.3 51.1 – 13.7 2.0 – 0.4
SQRM 1816 1841 1.2 – 0.3 17.8 – 3.5 2.5 – 0.5
SQRM 1821 1853 3.2 – 1.2 63.0 – 7.8 3.3 – 2.3
SQRM 2121 2141 3.8 – 1.9 207.0 – 22.9 2.9 – 1.0
c-kit-targeted SQRMs
SQRM 39 64 2.5 – 0.3 54.2 – 15.8 4.5 – 0.8
SQRM 137 163 1.3 – 0.1 4.6 – 1.0 1.1 – 0.2
SQRM 287 304 4.5 – 1.3 6.6 – 2.2 1.2 – 0.2
SQRM 351 381 3.0 – 1.1 11.5 – 4.4 N.D.
SQRM 580 607 1.8 – 0.4 16.4 – 3.4 N.D.
SQRM 663 683 7.4 – 3.0 4.5 – 2.2 0.8 – 0.3
SQRM 807 837 6.4 – 1.0 16.5 – 3.0 1.4 – 0.3
SQRM 924 946 3.1 – 0.6 7.2 – 01.2 0.8 – 0.1
SQRM 962 994 5.4 – 0.5 7.3 – 0.7 1.6 – 0.2
SQRM 1093 1116 4.1 – 0.4 4.7 – 1.7 1.5 – 0.4
N.D., no data.
All values – SD are the result of six trials unless otherwise noted.
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insigniﬁcant compared with the AS ODN 1190 1222.
To demonstrate that SQRM could identify hybridization
accessible sequence in living cells real-time, we microinjected
SQRM 321 350 and a scrambled SQRM control into the
hamster ﬁbroblast cells (TK
 ts13) engineered to express
c-myb. SQRMs were end-protected by phosphorothioate
linkages between the ﬁve outermost bases. The development
of ﬂuorescence was monitored post-injection every 10 min for
a total of 30 min. Representative photomicrographs are shown
for a cell injected with SQRM 321 (Figure 6). There was no
increase in ﬂuorescence detected 30 min after the injection of
scrambled SQRM (data not shown). In accord with previous
reports that oligonucleotides rapidly diffuse from cytoplasm
into nucleus (15), nuclear ﬂuorescence intensity increased as
cytoplasmic ﬂuorescence decreased. These results correlate
wellwiththeﬂuorescencelevelsobservedintheinvitroassays
with RNA targets. Of signiﬁcantinterest,they alsosuggestthat
Figure4. bcl-6invitroassays.(a)bcl-6RNaseHassayusingSQRM1190 1222.RNAwasincubatedwitheachSQRMandrunonanagarosegel.TheSQRM1190
successfullyrecruitsRNaseHtocleavetheRNAoftheRNA/DNAhybrid.(b)bcl-6SQRM1190wasincubatedwithvarioustargetsandthefluorescencesignalwas
measured. Louckes-1 (20 mg), Louckes-2 (40 mg) and K562 are RNA samples isolated from cell extracts. SQRM was also incubated with in vitro transcribed RNA
(IVT RNA; a positive control for SQRM/RNA hybridization) and an ODN (positive control for SQRM function).
Figure5. c-mybASODNsinvivo.AnASODNcorrespondingtotheSQRM321wassynthesizedandtransfectedintohamsterfibroblastTk
 ts13cellsengineeredto
express human c-myb.( a) The western blot shows a decrease in protein expression following treatment with the AS ODN 326–345 as compared with AS ODN
983–1000 (negative control). (b) Graphical representation of the western blot data: AS ODN 326 345 (green); AS ODN 983–1000 (gray).
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detected with these probes.
DISCUSSION
The difﬁculty involved in identifying hybridization accessible
sequence within RNA molecules in vivo has been a signiﬁcant
impediment to the development of AS ODN for either inform-
atic or therapeutic purposes. The widespread adoption of RNA
interference has ameliorated this problem to some degree, but
increasing experience with this methodology has shown that it
is often necessary to make numerous molecules before one
with considerable gene silencing activity is found. We believe
that those data presented in this manuscript allow us to state
that we have now made signiﬁcant progress in solving this
problem, at least in the case of AS ODN. The c-myb SQRM
321 350, for example, exhibited an acceptable signal-to-
noise ratio and outperformed all other c-myb SQRMs tested
(Figure 2). These promising results were further supported by
the cell-free in vitro coupled transcription–translation system
assay (Figure 3). When an antisense ODN that corresponds to
this SQRM was incubated with the cell-free mixture, a dra-
matic decrease in the target protein was seen. This was also
seen in vivo, where treatment of human c-myb-expressing
hamster ﬁbroblast cells with increasing concentrations of
AS ODN affected a decrease in protein expression after 24 h
(Figure 5). Furthermore, the hybridization was seen in vivo,
in real time, following microinjection of these cells with
SQRM 321 350 (Figure 6).
To further demonstrate the utility of the strategy we present
in this paper, two other mRNAs, the transcription factor bcl-6
and the PDGF family receptor c-kit, were also mapped using
the same procedures. In the case of bcl-6, efﬁcient silencing
was shown with SQRM 1190 1222, which exhibited the
greatest ﬂuorescence in vitro (Figure 2). The AS ODN cor-
responding to this SQRM sequence also yielded the best gene
silencing activity (an  7-fold mRNA reduction) as demon-
strated using real-time PCR. A western blot revealed a signi-
ﬁcant decrease in BCL-6 protein expression with AS ODN
1190 1222, but no signiﬁcant decrease in the case of all
remaining molecules. Interestingly, AS ODN 1190 1222
contains a G quartet in its sequence, which has been cited
as a cause of non-speciﬁc inhibition of cell function. However,
use of the appropriate controls, including a scrambled
molecule (33mer) with a G quartet and the same base content
as AS ODN 1190 1222, ruled this out because none had any
effect on bcl-6 expression (data not shown).
Nucleic acid-mediated gene silencing, employing various
types of targeting ‘vectors’ including AS ODN, ribozymes,
DNAzymes and short interfering RNAs, has been used with
considerable success in the laboratory (16–18). Many also
hope to employ nucleic acid-based gene silencing for thera-
peutic purposes, but important technical issues remain to be
solved before this approach will become reliable enough for
routine treatment of disease. These issues include the problem
of inefﬁcient delivery of molecules to targeted cells (19),
inability to intracellularly ‘address’ molecules to their
mRNA targets (20,21), and a limited ability to predict second-
ary and tertiary mRNA structure in vivo (22). Localizing
hybridization accessible sequences within any given mRNA
is complex since many unpredictable factors govern how these
molecules fold (23). Off-target silencing by siRNAs has
become a concern (24), particularly when used for functional
analysis of genomic/array data in the laboratory. As antisense
DNA does not enter the siRNA pathway, it may be more
speciﬁc than siRNA, while exhibiting similar levels of attenu-
ation. We believe that the work presented here provides a
useful approach to this problem and one that might, when
combined with efﬁcient methods for delivering these
molecules into cells, result in the development of truly useful
nucleic acid molecules for informatic and therapeutic usages.
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